This page shows the latest empagliflozin news and features for those working in and with pharma, biotech and healthcare.
In March, the US Food and Drug Administration (FDA) fast-tracked Farxiga’s rival Jardiance (empagliflozin), co-developed by Eli Lilly and Boehringer Ingelheim, to reduce the risk of kidney disease
The EMPEROR-Reduced trial evaluated SGLT2 inhibitor Jardiance (empagliflozin) in patients with heart failure with reduced ejection fraction (HFrEF).
Some outstanding questions include where vericiguat lies in relation to the SGLT2 inhibitors such as Boehringer Ingelheim/Eli Lilly’s Jardiance (empagliflozin) and AstraZeneca’s Farxiga/Forxiga (dapagliflozin), which are also
Jardiance (empagliflozin) is already approved to treat type 2 diabetes, but Lilly and Boehringer had been hoping to expand the number if patients eligible for treatment with the drug by making
Other drugs in the SGLT2 class – including Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) – are also being tested in heart failure indications.
Lilly’s SGLT2 inibitor Jardiance (empagliflozin) and Victoza, as well as placebo.
More from news
Approximately 16 fully matching, plus 84 partially matching documents found.
The remaining two SGLT2s are growing faster than the market, with Jardiance (empagliflozin) leading the market in terms of growth.
s empagliflozin, but AstraZeneca's strength is the wide range of oral diabetes products it has to offer, says Boulton.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...